SG3 Management’s NovoCure NVCR Stock Holding History

SG3 Management’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-11,000	Closed	-$810K	–	1254
2021 Q4	$826K	Buy	+11,000	New	+$1.1M	0.02%	529

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Nordwand Advisors Radnor, Pennsylvania $572M AUM 23.09% 1-Year Est. Return

SG3 Management's NVCR Position: Q1 2022 in Review

SG3 Management sold out of NovoCure (NVCR) in Q1 2022, closing a stake of 11,000 shares — an estimated $810K sold.

SG3 Management first reported a position in NVCR in Q4 2021 and held it in 1 quarter. The position peaked at $826K in Q4 2021. 309 funds tracked by Wall St. Rank hold NVCR as of Q1 2022.

SG3 Management reported no remaining NovoCure position as of Q1 2022 after selling out during the quarter.
SG3 Management sold 11,000 NovoCure shares in Q1 2022, an estimated $810K.
SG3 Management first reported a position in NovoCure in Q4 2021 and held it in 1 quarter.
SG3 Management's NovoCure position peaked at $826K in Q4 2021.
309 funds tracked by Wall St. Rank held NovoCure as of Q1 2022.

Based on SG3 Management's 13F filing for Q1 2022, filed 16 May 2022.